A recent phase 3 study found that venetoclax-obinutuzumab improves progression-free survival and quality of life compared with chlorambucil-obinutuzumab in patients with untreated chronic lymphocytic...
A recent phase 3 trial demonstrated that a personalized approach using ibrutinib-venetoclax therapy, based on measurable residual disease, improves progression-free survival and overall survival in patients...
Risk factors may give a clinician an idea of the chance their patient has of developing a disease, like chronic lymphocytic leukemia (CLL). There are few known risk factors linked to CLL. Do you know which...
Risk factors may give a clinician an idea of the chance their patient has of developing a disease, like chronic lymphocytic leukemia (CLL). There are few known risk factors linked to CLL. Do you know which...
While most cases of chronic lymphocytic leukemia are appropriately managed with medication therapy, rare cases require the use of additional treatment modalities. Which of these other treatments have you...
The American Cancer Society annually projects the number of new leukemia diagnoses in the United States. Which type of leukemia is projected to have the most diagnoses in 2024? Take the quiz to find out! ...
The survival outcomes for patients diagnosed with this chronic lymphocytic leukemia complication have remained poor for decades. Can you name the complication? Take the quiz to find out!
